Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Natile

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Inorganic Chemistry|April 16, 2002
Direct addition of alcohols to organonitriles activated by ligation to a platinum(IV) centerNadezhda A Bokach, Vadim Yu Kukushkin, Maxim L Kuznetsov, et al.
Dalton Transactions (Cambridge, England : 2003)|January 21, 2012
Modulation of properties in analogues of Zeise's anion on changing the ligand trans to ethene. X-ray crystal structures of trans-[PtCl2(OH)(η2-C2H4)]- and trans-[PtCl2(η1-CH2NO2)(η2-C2H4)]-Michele Benedetti, Carmen R Barone, Daniela Antonucci, et al.
Dalton Transactions (Cambridge, England : 2003)|July 12, 2016
Anticancer potential of a photoactivated transplatin derivative containing the methylazaindole ligand mediated by ROS generation and DNA cleavageJitka Pracharova, Tereza Radosova Muchova, Eva Dvorak Tomastikova, et al.
Inorganic Chemistry|October 24, 2001
Chirality-Controlling Chelate (CCC) Ligands in Analogues of Platinum Anticancer Agents. Influence of N9 Substituents of Guanine Derivatives (G) on the Distribution of Chiral Conformers of (CCC)PtG(2) with CCC = N,N'-Dimethyl-2,3-diaminobutaneLuigi G. Marzilli, Francesco P. Intini, Danita Kiser, et al.
International Journal of Molecular Sciences|April 2, 2020
Platinum(IV) Complexes of <i>trans</i>-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer ResistanceParide Papadia, Katia Micoli, Alessandra Barbanente, et al.
Dalton Transactions (Cambridge, England : 2003)|April 21, 2016
Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micellesNicola Margiotta, Salvatore Savino, Nunzio Denora, et al.
Angewandte Chemie (International Ed. in English)|December 31, 2013
Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7BFrancesco Tadini-Buoninsegni, Gianluca Bartolommei, Maria Rosa Moncelli, et al.
Molecules (Basel, Switzerland)|July 2, 2021
New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro CytotoxicityAlessandra Barbanente, Rosa Maria Iacobazzi, Amalia Azzariti, et al.
Angewandte Chemie (International Ed. in English)|November 20, 2021
<sup>19</sup> F NMR Allows the Investigation of the Fate of Platinum(IV) Prodrugs in Physiological ConditionsSiming Yuan, Yang Zhu, Yi Dai, et al.
Journal of Medicinal Chemistry|June 23, 2007
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12Rossella Sasanelli, Angelina Boccarelli, Domenico Giordano, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Inorganic Chemistry|April 16, 2002
Direct addition of alcohols to organonitriles activated by ligation to a platinum(IV) centerNadezhda A Bokach, Vadim Yu Kukushkin, Maxim L Kuznetsov, et al.
Dalton Transactions (Cambridge, England : 2003)|January 21, 2012
Modulation of properties in analogues of Zeise's anion on changing the ligand trans to ethene. X-ray crystal structures of trans-[PtCl2(OH)(η2-C2H4)]- and trans-[PtCl2(η1-CH2NO2)(η2-C2H4)]-Michele Benedetti, Carmen R Barone, Daniela Antonucci, et al.
Dalton Transactions (Cambridge, England : 2003)|July 12, 2016
Anticancer potential of a photoactivated transplatin derivative containing the methylazaindole ligand mediated by ROS generation and DNA cleavageJitka Pracharova, Tereza Radosova Muchova, Eva Dvorak Tomastikova, et al.
Inorganic Chemistry|October 24, 2001
Chirality-Controlling Chelate (CCC) Ligands in Analogues of Platinum Anticancer Agents. Influence of N9 Substituents of Guanine Derivatives (G) on the Distribution of Chiral Conformers of (CCC)PtG(2) with CCC = N,N'-Dimethyl-2,3-diaminobutaneLuigi G. Marzilli, Francesco P. Intini, Danita Kiser, et al.
International Journal of Molecular Sciences|April 2, 2020
Platinum(IV) Complexes of <i>trans</i>-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer ResistanceParide Papadia, Katia Micoli, Alessandra Barbanente, et al.
Dalton Transactions (Cambridge, England : 2003)|April 21, 2016
Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micellesNicola Margiotta, Salvatore Savino, Nunzio Denora, et al.
Angewandte Chemie (International Ed. in English)|December 31, 2013
Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7BFrancesco Tadini-Buoninsegni, Gianluca Bartolommei, Maria Rosa Moncelli, et al.
Molecules (Basel, Switzerland)|July 2, 2021
New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro CytotoxicityAlessandra Barbanente, Rosa Maria Iacobazzi, Amalia Azzariti, et al.
Angewandte Chemie (International Ed. in English)|November 20, 2021
<sup>19</sup> F NMR Allows the Investigation of the Fate of Platinum(IV) Prodrugs in Physiological ConditionsSiming Yuan, Yang Zhu, Yi Dai, et al.
Journal of Medicinal Chemistry|June 23, 2007
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12Rossella Sasanelli, Angelina Boccarelli, Domenico Giordano, et al.
Pageof 16